ImmunoPrecise is excited to be exhibiting at this year’s Discovery on Target conference from September 25th to 28th in Boston, MA. Visit booth #213 at the Sheraton Boston, and discover how ImmunoPrecise can further your therapeutic antibody development. With over 1,300 drug discovery professionals in attendance, representing over 20 different countries, DOT 2018 is the perfect opportunity to learn, connect, and share information in this rapidly expanding and constantly developing field.
Click here to schedule a meeting with one of our delegates from ImmunoPrecise or Modiquest Research!
Meet with one of our representatives to discuss our featured services
- B-cell Select
- Human Monoclonals
- Advanced Hybridoma Development
- Phage Display
- Rabbit Monoclonals
- Rapid Prime Immunization
- Genetic Immunization
- Antibody Characterization and Optimization
- Antibody Engineering
- Protein & Antibody Expression
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery. We deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands.
Set up a meeting to learn more!
About Discovery on Target
The 16th Annual Discovery on Target, “The Industry’s Preeminent Event on Novel Drug Targets,” will once again gather over 1,300 drug discovery professionals in Boston, MA, this September. The event brings forth current and emerging “hot” targets, technologies and validation strategies for the development of novel small molecules and biologics.